News
(3)April 2026
Skye Bioscience, Inc. — PREM14A Filing
# 🧾 What This Document Is This is a **preliminary proxy statement (PRE14A)** for Skye Bioscience. Think of it as an invitation and information packet for the company's annual shareholder meeting. Its main job is to ask shareholders to vote on key proposals, like electing directors and approving com
Skye Bioscience, Inc. — PRE 14A Filing
Here's a clear breakdown of Skye Bioscience's PRE 14A filing: # 🧾 What This Document Is This is a **preliminary proxy statement** for Skye Bioscience's 2026 Annual Shareholder Meeting. It outlines proposals shareholders will vote on and provides essential company information. Think of it as the ag
Skye Bioscience, Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is a report public companies file with the SEC to announce major events that shareholders should know about. In this case, Skye Bioscience is reporting that it has entered into a **Master Services Agreement** with a consulting firm called *
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.